Citigroup Maintains Buy on Rigel Pharmaceuticals, Lowers Price Target to $69
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Citigroup analyst Yigal Nochomovitz maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and lowers the price target from $71 to $69.
Citigroup analyst Yigal Nochomovitz maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and lowers the price target from $71 to $69.